Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)

NCT05931276 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

NCT NCT05931276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05931276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)
Lead sponsor
VA Office of Research and Development
Phase
Phase 3
Overall status
Recruiting
Start date
May 22, 2024
Completion date
December 31, 2028
Enrollment
2,540 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

end-stage kidney disease, end-stage renal disease